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The cellular distribution of mRNAs for urokinase-
type plasminogen activator (uPA), its specific recep-
tor (uPAR), and its inhibitors (PAI-l and -2) in mouse 
skin was analyzed by in sitlt hybridization after topical 
application of the tumor promoter phorboI12-myris-
tate 13-acetate. In the epidermis, strong signals for 
uPA and PAI-l mRNA were detected 24 h after 
treatment in the basal and suprabasal epidermal ke-
ratinocytes in areas with pronounced hyperprolifera-
tion and increased terminal differentiation, and in 
some hair follicle keratinocytes. After 48 h, both 
uPAR and PAI-2 mRNAs were expressed in the epi-
dermal layers from the suprabasal keratinocytes up to 
the differentiating cells beneath the cornified layer 
and in hair follicle keratinocytes. Induction of P AI-2 
mRNA was detected in epidermis as early as 3 h after 
treatrnent and remained stable for up to 7 days. In the 
dermis, 5 h after application of phorbol 12-myristate 
13-acetate to the skin, uP A mRNA was detected in 
fibroblast-like cells below and around the skin mus-
cle, and PAI-l mRNA was detected in stromal cells 
I nvasion of cancer cells requires degradation of the extracel-lular matl;x. Of the several proteolytic enzymes involved in this process (Dan0 e/ ai, 1985; Mignatti and R.ifkin, 1993), the serine prote inase urokinase-~ype pla sminog~n activator (uPA) and members of th e matrL">: m etalloprotemase fumtly 
are the best studied . uPA plays an important role in a numbe r of 
physiologic conditions in which degradation of the extracellular 
matrix is required for tissue remodeling and cell migration, e.g., 
wound healing, in volution of the mammary gland, trophoblast 
implantation, and invasion of can cer cells (Dan0 el ai, 1985; 
Mignatti and Rifkin, 1993). The tempora l and spatial enzymatic 
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located above the skin muscle. After longer exposure 
to phorbol 12-myristate 13-acetate, the PAI-l mRNA-
expressing stromal cells were located more superfi-
cially, apparently moving toward the epidermal 
layer. After 9 h, most of the PAI-l mRNA-positive 
cells were identified as endothelial cells. Up to 24 h 
after the application of phorbol 12-myristate 13-
acetate, the intensity of the signal for both uPA and 
PAI-l increased, followed by a gradual decrease for 
up to 7 days. These results show that in mouse skin 
treated with a tumor-promoting phorbol ester, the 
various components of the plasminogen activation 
system are expressed by both epithelial and stromal 
cell types, which in dermis and subcutis are located in 
different places, depending on the time of exposure 
to the phorbol ester. Our results suggest that uroki-
nase-rnediated extracellular proteolysis has diverse 
functional roles during the early steps of tumor pro-
motion. Key words: plasllli1logell actilmtionlclrell,.ical cQrci-
1wgctlesislplwl'bol IIIY"ista tc aceta leIs lm III a l-epU/lei iaJilltel'-
actiolls. ] Invest Dennatol 106:622-630, 1996 
actIvI ty of uPA is ,·egulatcd by two specific inhibi to rs, PAI-1 and 
PAI-2. both belonging to the serpin class of inhibitors (Andreasen 
et ai, 1.990), and by a specific cell-sur£1 ce receptor. uPAR (Vass:llli 
cl ai, 1985). uPAR is a cysteine-rich , highly glycosylated protein 
attached to the ce lJ surface by a phosphatidylinositol g lycolipid 
anchor (Behrendt c/ ai, 1990; Plollg ef ai, 1991; Solberg e/ ai, 1992). 
Complete human and mouse uPAR cD NA s have been isolated 
(Roldan el ai, 1990; Kristensen el al. 1991 a). lIPAR binds both 
active uPA and its virtua ll y inactive proenzyme form. pro-uPA, 
with high a ffinity . Pro-uPA ca n be activated to uPA by plasmin 
w illie bound to uPAR, and receptor-bound uPA in turn activates 
plasminogen (Blasi el ai, 1987). Concomitant bindin g of pro-uPA 
and plasmirlOgen to the cell surC,ce acce le rates phlSlninogen acti-
vation (Ellis 1:/ al. 1.991.) . making the cell surface the prefe rential site 
for the urokinase pathway of plasminogen activatio n [for reviews 
see Ellis and ])an0 (1991) and Dan0 el ai, (1994)]. Thus, regulation 
of the lJPA system becomes complex when it is considered that, 
under physiologic conditions, its variolls compon ents are expressed 
not necessarily b)i the same cells but often by various types of 
neighboring cells (Dan0 c/ (I I , 1994). 
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It is likely that cytokin es playa c rucia l role in the regulatio n of 
the uPA system , b oth in t issue remodeling during n o rma l physio-
logic events and during cancer in vas ion. A lthough th e e ffects of 
hormones, cytokines, and t um o r pro m oters o n the expression of 
va r io us components of the PA system have been studied in detail ill 
v itro [fo r reviews see Andreasen ct ai , (1990), Saksela and Rifkin 
(1988), and Laiho and Keski-O j" (1989)], o nly a few studies h ave 
been d evoted to the ir effects ill /li/lo (Quax et ai , 1990; Sawd ey and 
Loskutoff,1991). 
Mouse skin has been used extensive ly as an ill /li/lo model system 
for e luc idating the tumor-promoting ro le of PMA during ch e mical 
carcinogen esis. Topica l app li catio n of a sing le dose of PMA o n 
mo use skin elicits a stro n g pleiotropic response in the e pide rmis and 
dermis, including in creased proliferatio n of the basa l keratinocytes , 
fo llowed by a h ype rplastic response and inflammation and an 
increased rate of terminal dilfe re ntiation of t he keratinocytes (Pot-
ten, 198 1; Slaga. 1983; Reiners and S laga, 1983; Yuspa and P o il'ier, 
1988). Indu ction of the express io n of Va l'iOU S gen es by PMA 
trea tment, including transforming g rowth facto r-{31 mRNA and 
protein (Akhurst el. ai , 1988; Fowlis Cf ai, 1992; K rieg c f ai, 1991.), 
interleu k.in-l a (Oberyszyn et ai, 1993 ), c-Jos and C- IIIJ1C (Rose-John 
et ai, 1988), stro l11 e lysin-1 (Ostrowski ct ai, 1988; Wright ef ai , 
1994), and osteopontin (Craig et ai, 1989), as well as d efects in the 
regul ation of dilferentiation and proliferation in initiated keratino-
cytes, are con sidere d key events in early tumor developmen t of the 
epidermis [Yuspa and Poirier (1988); for review, see Bowden and 
Krieg (1991)]' The effect of PMA on gen e expression ha s also been 
stu die d intensive ly in cell c ulture system s, where it was early shown 
to increase plasminogen activator activity in H e La cells (Wigle I' and 
Weinstein, 1976). Later it was shown that PMA also indu ces 
mRNA and protein fo r PAI-1 (Lund el ai, 1988; Mayer et ai , 1988), 
uPA (Stoppe lli et ai, 1986), and uPAR (Lund et ai, 1991 b , 1995; 
Picon e el ai, 1989) in som e but n ot all teste d cell lines, su ggestin g 
a cell-specific respo n se to PMA treatm ent. 
By immunohistoche mical an alys is and ill sil ll h ybridization , we 
have previously sho wn that PAI-l and uPA mRNA and protein are 
differe ntially and specifi ca lly induced in the basal and su prabasa l 
ke ra tillocytes, respective ly, during re- e pitbelia liza tion of mouse 
skin wounds (Gnmdahl-Ha nsen et al. 1988; R.e m e r et ai, 1991), 
w hereas uPAR is ex p ressed b y the lea ding edge of keratinocytes 
(Remer et ai, 1994). T hese o bservation s suggest a tightly regulated 
expression of the vario us components of the pl asmill ogen activation 
sys tem in m o use skill durin g ti ssue remod e li ng, inflammatio n , and 
cell migration b y unknown factors . Because ill ,)ilro studies do n ot 
always re fl ec t the situation ill II;'J() , we h ave extende d our previo us 
ill ,Jil/'o studies of the regulatory e ffects of PMA o n expression of the 
variou s compo ne n ts of the PA system . H e re we re port the sh ort-
term elfects of topical application of PMA to m o use skin on th e 
express ion of uP A, uPAR, PAI-l, and PA I-2 mRN A as d etected by 
i'l sitll h ybridizatio n. 
MATERJALS AN D METHODS 
Materials PMA and PMA 4- 0 -mcthyl ether were obta ined from Sigma 
Chem ical Co. (St. Louis, MO) T7. T3, and SP6 polymerase, DNase I. a 
random priming DNA kit, dithiothreitol, restri ction endonucleases. and a 
monoclonal antibody directed agai nst a macrophage-specific antigen 
(Mac-1) were obta ined fi:om Boehringer (Mannheim , Germany). All other 
materials were described previously (Kristenscn ef nl , 199 '1 a, b; Lund c/ nl , 
1991a, 1995; R..e mer ('I nl, 199 1, 1994). 
Animal and Tissue Treatluent Procedures. T he mice used wcre 8-
to 1 O-week-old femalc BALB/ c (Fibiger Institute, Copenhagen Denmark), 
kept in animal housing filc ili ties at 25 ::':: 2°C, 55 ::':: 5% humidity with an 
artificial day-night rhythm of 12 h each. and fed standard food pellets 
(Altromin number '1 314. obtained from hI'. Petersen , Ringsted, Denmark) 
and water nd libillllll . T he backs of the mice were sha ved the day before the 
onset of the experiments. which all started at 9 a. m. pMA (6 .25 ILg) was 
ap plied topica lly in 200 ILl of acetonc and covered the shaved area 
completely (approximate ly 3 cm2) . Contro l mice were un treated or treated 
w ith solvent (200 ILl ofacctone) alone. T he mice used for RNA preparation 
or prote in extraction were anesthetized with die th),lcther iml11ediately 
be fore usc and perfused in tr;Jca rdially with 20 1111 of icc-cold phosphate-
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buff'ered sa linc (PBS) . T he dorsa l skin was rcmoved and immediately frozen 
in an ethanol/dl) ' icc bath or in liquid nitrogen and then stored at - 80°C 
until RNA purificatio n o r extractio n of prote ins. Skin fronl t\vo rnicc in 
each group was used. 
Mice used for ill situ hybrid ization or inl l11Ullohistochcll,jca l analysis \vere 
treated w ith PMA for periods of 3 h to 7 days (at least two mice per 
treatment group) or with PMA 4-0-methyl ether for 24 or 72 h. Control 
mice were untreated or treated w ith so lvent alone. T he mice were treated 
as described abovc. except that after perfusion with ice-cold PBS they were 
intracardially perfused with 20 ml of 4% (w i v) parafonnaldehyde in PBS. 
T he treated sIGn \vas rc rnovcd and cu t into slices. T hese spcc inlc lls ' ,vere 
post-fixed fo r 16 h in 4% parafonnaldehyde in PBS and processed for 
paraffin embedding. All experiments were performed according to protocols 
approved by the Danish Animal Research Commi ttee. 
Preparation of RNA Probes T he fo llowing fi'agm ents of mouse uPA 
cDNA (Belin c' nl, 1985) , mouse PAI-1 cDNA (Prendergast and Cole. 
1989), mouse PAI-2 cDNA (Belin ef nl, 1989) , and mouse uPAR cD NA 
(Krisrcnsen CI nl, 1991 a) were subcloned: for uPA, pMUPA07 fragment 
(608- 1642) in pGEMSz, or pMUPA09 fragment (37-428) in pBluescript 
KS( + ) (Kristensen et nl, 1991b); for PAl-I. pl11PAl102 fragment (6-338) or 
pmPAI1 03 fi'agment (338-857) in pBIuescript KS (+ ); for PAI-2, pmPAI21 
fragment (188-453) or pmPAI22 fi'agment (616-931) in pBluescript KS 
(+ ); for uPAR , p50A/1 P-X fragment (151-362) or p50A12XB fragment 
(362- 461) in pBluescript KS (+ ). T he last two plasmids are fi'agments of 
mouse upAR cDNA covering sequences that are identica l iUl110use upARl 
and uPAR2 (Kristensen cl nl, 1991 a) . e SSjUTP antisense or sense probes 
wcre generated by transcription of the plasm ids with the relevant polymer-
ase (SP6, T3 , orT7) as described previously (Kristensen el nl. 1991b). Probe 
concentration was always more than 2 X 10(' cpml ILl , alld the activity of the 
two corresponding RNA probes transcribed from the opposite strand of the 
same plasmid was adjusted to the same radioactivity concentration . Labeled 
probes were stored at - 20°C until usc. 
I" Sit" Hybridization 111 Silll hybridization was performed as described 
in derail previously (Pyke "I nl, 1994). BrieRy, 5-ILm para/tin-embedded 
sections of the skin on chrome-alun gelatin-coated or Superfros t+ slides 
were deparafrinizcd in " .. y lene and treated with proteinase K. After hybrid-
ization ovem ight with the labe led RNA probe, the sections were washed. 
treated with RNase A and RNase T I • dehydrated, and air-dried . Autora-
diographic ellluision was app lied, and sections were developed after J 0 days 
of exposure. 
RNA Isolation and Analysis Tota l RNA was purified by the method of 
C homczYlISki and Sacchi (1987) . Poly(A) + RNA was obta ined by purifica-
tio ll on poly(dT) columns as described previously (Re mer ('( nl. 1991). 
Specific III RN A was detected by reverse transcription-polymerase chain 
reaction (RT-PCR). Poly(A) + R..NA (50 ng) was reverse-transcribed ill 
20 ILl of reverse trallScl;ptase buffer, containing 10 ILM random hexade-
oxynucleotides, IOU of R.nasin . and 10 U of avian myeloblasros is virus 
reverse transcriptasc for 45 mill at ·n oc. T hese cD NA preparations were 
di lu ted 10-fold , and 1 O-ILI aliquots were added to the PCR reactions: PCR 
buff'er (10 mM Tris/ HC I. pH 9.0.50 mM KCI, 2.0 mM MgC I2), 0.00 1';;', 
(w l v) gela ti n, 0.0 1% (v l v) Triton X 100. 200 ILM concentration of each 
deo,,),nucleotide. 25 pmol of cach primer. and 1 U ofTaq polymerase in a 
tota l vo lul1le of 100 ILl. PCR ampli fication proceeded for 30 cycles: 94°C 
fo r 45 s. 55°C (uPAR primers) or 45 °C (uPA and PAI-l primers) for 45 s, 
72°C fo r 45 s. T he PC R primers for murine uPAR.: nucleotides 392-410 
and 714-735 (Kristensen el nl. 199 'l a); for uPA: nucleotides 404-427 and 
1,001-1 ,024 (Belin el nl. '1 985); fo r PAl-I: lIucleotides 512-528 and 
992-1 .008 (Prendergast and ole. 1989): for PAI-2: nucleotides 490 - 5 11 
and 782-802 (Belin el nl, 1989); and for {3-actin: nucleotides 25-44 and 
246-270 (AlolISo ," nl, 1986) . The PCR products were subsequently 
electroblotted onto a GeneScreen nylol1 mcmbrane afrer agaros" gel 
electrophoresis and denaturation. Polynucleotides were cross-Ii li ked to the 
membrane by UV ti ght and hyb6dized wi th '5S-labeled IIPAR, uPA , PA l-I. 
PAI-2 , or {3-actin cDNA probes in a hybridization so lution as described 
previously (Solberg cf nl , 1992). 
R ESULTS 
Histologic Changes of the Mouse Skin After a Single Treat-
Inent with PMA T he first v isible morphologic changes that 
followed a sing le topical ap pli cation of the tumor promoter PMA to 
the b acks ofBALB/c mice were marked e l) ,the ma and edema of t he 
affected areas of the skin . Within dle first 3-5 b after treatment, 
there was a dramatic influx of inA amJ11ato ry cells, mainly n e utro-
phils, to the subc utis and lower dermis be low the treated area (Fig 
lB) , whereas mi ce treated with solvent alo n e had no suc h reac tion 
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Figure 2. uPA and PAI-l mRNA expression in nlouse epidermis 48 h after PMA treatment. Sections of PMA-treatcd mo use skill showing 
hybrid iza tion for L1PA I11~A (a and b) and PAI-l mRNA (c and d) in the epidermal keratinocytes . T he ti ssuc sections arc viewed with cither light- tie ld (a 
and c) or dark-field (b and d) microscopy. Note that the signa ls for uPA and PAI- l mRNA arc res tricted to the basal and somc suprabasa l kcratinocytes . Scale 
bar, 10 p.m. 
(Fig lA) . T h e m aximal influx of infiammacoI), cells to the d emlis 
was seen 16 to 24 h after treatment (Fig lC) . Inflammatory cells 
wer e also d e tected in the epidermis, interspe rsed among the 
differentiated ke ratinocytes (data not shown). Up to 72 h after PMA 
treatmen t, the numbe r of inflamm atory cells gradually decreased 
(Fig lD), and after 7 days the numbe r of inflammatory cells was 
comparable to that seen in the solven t-treated contro l mice. As 
judged by m o rpho logic criteria, ini tiation of cell divisio n in basal 
epid erma l keratinocytes and onset of term inal differentiation were 
obviolls within the first 24 h a fte r PMA trea tment (Fig lC) , and 
after 72 h the epide rmis con sisted of severa l la yers of keratinocytes, 
including a basa l laye r and four to six laye rs of diffe rentiating 
suprabasa l cells (Fig lD). There was no detectable e ffect of the 
non-tumor-promoting phorbol ester PMA 4-0-meth yl ether after 
24 or 72 h (data n ot shown ). 
uPA, uPAR, PAl- l, and PAl-2 mRNA Expression in Mouse 
Skin Exposed to PMA, as Detected by ill Sit" Hybridization 
Epiderlllis Twenty- four bours afte r the application of a single dose 
of PMA, a strong signal for PAI-l mRNA was detected in basal 
keratinocytes b e low areas w ith h yperprolife ration and increased 
tennina! diffe re ntiatio n. Forty-eight h ours after PMA treatment, 
uPA mRN A was also present in basal and som e suprahasa l differ-
e ntiating keratinocytes as we ll as ill som e hair fo llicl e keratinocytes 
(Fig 2, a-d) . Both uPA and PAI-l In R.N A expression wa s still 
detected in the ke ratin ocytes for up to 7 days (data not shown) . 
Figurc 1. Histologic changes ofBALB/c mouse skin aftcr a singlc topical application ofthc tUInor promotcr PMA. Hematoxylin-eosin sraining 
of sections from BALB /c mouse skin treated with solvcnt alone fo r 72 h (A ) or with a single app l.i cation of PMA for 5 h (B), 24 h (C). or 72 h (D). E and 
F, higher magni fications of the marked areas (brokell · I;II" sq,,"ro) of the lower dermis in A and B, respectively. Note the pronounced influx of inflammatory 
cells to dermis 5 h after PMA treatm ent (B and F) compared with the so lvent-treated skin (A and E). A I1'01" in D, hyperplas ia imd increascd tenninal 
di1ferentiatio l1 of the epidermis. A 'TOIII in P, extrav"satio l1 of inA"mmatory ce ll s from a small vessel in the lower dennis. A, B, C. and D: Scale IJar. 50 p.m. 
E and F: Scale (Jar, 10 (.J.m. 
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Figure 3. uPAR and PAI-2 mRNA expression in mouse epidernlis 48 h after PMA treatlnent. Sections of PMA-treated mouse skin showing 
hybridization for uPAR mRNA (a and b) and PAI-2 mRNA (c and d). The sectio ns are viewed by ught-field (a and c) or dark-field (b and d) microscopy. 
Note that botb uPAR and PAI- 2 mR.NA arc expressed by the suprabasaJ kera tinocytcs and by the differentiating ce ll s beneath the co rnified layer. Scale bar, 
10 JLm. 
Forty-eight bours after exposure to PMA, uPAR mRNA expres-
sion was de tected in epidermal keratinocytes and in some hair 
foUicle keratinocytes. The highest expression in epid ermis was seen 
in the layers of differentiating cells above the basal keratinocytes 
and beneath the comified layer (Fig 3, a and iI). At later times the 
intensity of the signaJ for uPAR mRNA decreased. 
After only 3 h of PM A treatment, a very strong signal for PAI-2 
mRNA was detected in the differentiating keratinocytes above the 
basal layer and in hair follicles . After 48 h the signal for PAI-2 
mRNA was confined to the supra basal layer and the layers of 
keratinizing cells beneath the cornified layer: (Fig 3, c and tf), and 
it remained highly expressed for up to 7 days (data not shown). 
The signals for uPA, uPAR, PAl-I, or PAl-2 mRNA were below 
detections limits for in sitll hybridization in the epidermis of 
untreated mice, mice treated with non-tumor-promoting phorbol 
esters, or mice treated with solvent alone (data not shown). 
Derlllis nlld SlIliCIIlis Expression of uPA and PAI-l mRNA was 
induced in cells located in the dermis and subcutis a few hours after 
application of PM A to the dorsal skin. Five hours after exposure to 
PMA, uPA mRNA was present in distinctive fibroblast-like cells 
located below and between the muscle cells of the musculus 
panniculus (Fig 4, a and iI) . At the same time, PAI-l mR.NA was 
seen in stroma'! cells located above the skin muscle (Fig 4, c and tf). 
Nine hours after exposure to PMA, there was a marked i.ncrease in 
the intensiry ofPAI- l ml~NA expression in individual cells and an 
increase in the overall number of positive cells. Most of the cells 
expressing PAI-l mR.NA were accumulating in the upper dermal 
layer and could be identified as endothelia l cells (Fig 4, e and J) , 
whereas the rest of these cells remained unidentified . Staining of 
adjacent sections with a macrophage marker (a-Ma c-I IgG) re-
vealed that the cells positive for uPA and PAI-l mRNA were not 
macrophages (data not shown). Between 24 hand 7 days after 
exposure to PMA, there was a gradual decrease in the intensity of 
both the PAI-l and uPA mRNA signals in the dermis. In general, 
more pronounced effects on uPA and PAl-l mRNA expression 
were obtaiJled when a higher dose of PMA was used, but it then 
resulted in toxic side effects such as pronollnced edema, necrosis, 
and partial separation of the epidermis from the de rmis (data not 
shown). No uPAR or PAI-2 mRNA was detected in dermis or 
subcutis lip to 7 days after application of PMA. 
No hybridization signals for uPA or PAl- l mRNA were detected 
in the dennis of untreated mice or mice treated with solvent alone 
(data not shown). 
Control ExperiUlents The specifi city of the signals for each of 
the mRNAs was supported by virtually identical results obtained 
with antisense RNA from two different, nonoverlapping cDNA 
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Figure 4. uPA and PAI-l mRNA expression in 
stronlal cells in mouse skin 5 h after PMA treat-
ment. [II silll hybridization for uPA mRNA (a and b) and 
PAI-l mRNA (c and rI) in adjacent sections of mouse skin 
afte r treatment with PMA for 5 h and for PAI-l mRNA (<' 
and) after treatment with PMA for 9 h. The sections are 
viewed by light-field (a, c, and e) or dark-field (b, d, and 
.I) microscopy. Note the localization of uPA mRNA in 
fibroblast-like cell s below or between the skin muscle 
(an'OI"s in a and b), whereas PAI-l mRNA was seen in 
stromal cells more superficially located above the skin 
muscle (c aud rI). After 9 h of PM A treatment, the number 
of PAl-I-expressing cell s had increased and they were 
located in the upper part of the dem1is (e and 1; ano"'s 
show PAl-l mRNA in endothelial cell s). Scale bar. 10 !L1ll. 
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Figure 5. RT-PCR detection of uPA, uPAR, PAl-l, and PAl-2 
mRNA in extracts of mouse skin treated witb PMA. Southem blot 
analysis ofRT-PCR-amplifi ed ml1...NA isolated from either solvent-treated 
skin (Ial/e 1) or skin treated with PMA for 5 h (/al/ e 2). 24 h (/nl/ e 3). Or 48 
h (/fl//e 4). tl1...NA served as a negative control (Inl/e 5). and uPA eDNA (A). 
uPAR cDNA (B). 1'1'.1-1 cDNA (C). PAI-2 cDNA (D). and (3-actin eDNA 
(E) were used as positive controls (/nl/e 6) . The PC R products were 
generated witb primers specifi c for each cDNA as described in Mnrerials allli 
Methods. They were transferred to a nylon membrane and hybridized with 
35S-labcled probes . The hybridiza tion ortbe (3-actin eDNA probe was used 
as a control for the quality and amount ofmRNA used ill the RT-PCR with 
mouse- specifi c (3-actin primers (E). 
clones. The corresponding sense RNA probes were used as nega-
tive controls, and all showed no specific hybridization signal (data 
not shown). 
uPA, uPAR, PAI-l, and PAI-2 mRNA in Mouse Skin 
Extracts Total RNA was extracted from normal, full-thickness 
mouse skin and from mouse skin treated with a single dose of PM A 
for 5, 24, or 48 h. Poly(A) + RNA was isolated and analyzed by 
RT-PCR analysis with uPA-, uPAR-, PAl-l-, and PAI-2-specific 
primers as described in Materials arlll Methods. The PCR products 
were separated by agal'ose gel electrophoresis and analyzed by 
Southern blotting with uPA, uPAR, PAl-I , and PAI-2 cDNA 
probes, Although this very sensitive method is only semiquantita-
tive, it showed a strong induction of uPA and PAI-2 mRNA after 
the PMA treatment. As shown in Fig SA, a low level of uPA 
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mRNA was detected in normal ski.n, and a strong increase was 
observed after 5, 24, and 48 h of PMA treatment. uPAR mRNA 
was de tected both in untreated mouse skin and in PM A-treated 
skin; however, only the uPAR 1 form was detected (Fig SB) , A 
modest increase of PAI-1 mRN A was observed after PMA treat-
ment (Fig sq, and a very strong increase of PAI-2 mRNA was 
observed (Fig SD). Hybridization signals with simihll' intensity 
were observed in all samples when {3-actin-specific primers were 
used in the PCR (Fig SE), showing that the rnRNA from the skin 
extracts was intact. 
DISCUSSION 
We have demonstrated that mRNAs for all the components oftlle 
uPA-catalyzed plasminogen activation pathway are induced, in a 
potent, fast, and widespread manner, in the pleiotropic response of 
mouse skin to a single topical application of the tumor promoter 
PMA. 330th the spatial and temporal expression patterns differed for 
each component, suggesting diverse functional roles of urokinase-
catalyzed proteolysis in the skin jn response to PMA treatment. 1\1 
the epidermis, induction ofPAI-2 mRNA was detected remarkably 
early, at only 3 h after application of PMA, whereas uPA , uPAR, 
and PAI-l mRNA expression was detected somewhat later. The 
strongest signals for uPA and PAI-l mRNA were seen in the basal 
layer of keratinocytes, in contrast to the pattern of expression for 
uPAR and PAI-2 mRNAs, which were seen in the more superficial 
cell layers of epidernlis. The functional role of the urokinase system 
in the keratinocyte response to PMA treatment remains to be 
resolved, but it is possible that urokinase-m ediated proteolysis i 
involv ed in the accelerated continuous shedding of the corn.ified 
layers of epidermis by release of the interceHular desmosomal 
connections between keratinized celis. In view of our previous 
findings of uPA, uPAR, and PAI-1 expression in the migrating 
keratinocytes during re-epith elialization of mouse skin wounds 
(R0!11er et III, 1991, ] 994) and of uPA (Sappino e/ al, 1991; Miller 
et ai, 1992) and uPAR O. R0mer, unpublished observation) in the 
invading cancer cells of squamous skin carcinomas, a picture i 
emergillg that extracellular proteolysis generated by receptor-
bOllnd uPA at the cell surface is implicated in the migration of 
keratilJOcytes and squamoLls cancer cells. Tllis would take place by 
release of cell-cell and cell-substrate contacts, whether the cells are 
moving into a wound, infiltrating the surroundings of a skin 
carcinoma, or shedding from the superfIcial cornifIed layer of 
PMA-treated epidermis. 
In a recent study it was found that the matrix metalloproteinase 
strOl11.elysin-l was induced ill a subset of dermal fibroblasts and in 
some basal keratinocytes within 6 h of PMA treatment and with 
maximal effect at 16-20 h, suggesting that the elfect on stromely-
sin-l expression is more transient than the effect on the various 
components of the plasminogen activation system (Wright et al 
1994). The different time course of induction and localization of the 
strol11elysin-1-positive fibroblast-like cells in the upper dermal 
compartment makes it h.ighly unlikely that tbe same cells are 
positive for uPA or PAI-l and stromelysin-l and suggests that they 
have different induction pathways and functional roles. There is a 
shift in expression of stromelysin-l from stromal cells to cancer 
cells during the conversion from squamous to spindle carcinomas 
during chemical skin tumor progression (Wright cl aI, 1994). 
Future experiments are required to confirm that there is a similar 
shift in expression of the various components of the urokinase-
catalyzed plasminogen activation system during skin tumor 
progression . 
The early induction and widespread expression of uP A and PAl-l 
but not llPAR and PAI-2 were also seen in the dermis and subcutis. 
uPA and PAI-l mRNA was detected in stromal cells in dennis and 
subcutis 5 h after application ofPMA. uPA mRNA was detected in 
fibroblast-like cells. The cells positive for PAf-l mRNA were seen 
to move toward the upper part of the dermis at later times, when 
many of the cells were identified as endothelial cells. The fast 
induction of uPA and PAl-l l11RNA was not restricted to the 
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mRNAs; an increase in both uPA and PAI-l prote in levels was 
detected by direct and reverse fibrin zym ogrnphy, respectively 
(data not shown). T he fast induction of uPA and PAI-l in the 
dennis is comparable to that of early response genes, but the 
func tional significance o f this observation remains to be es tablished. 
T he localizatio n o f PAI-2 mRN A to the keratiniz ing cell layers 
of PMA-treated e pide rmis and to the superfi cial la ye rs of psol'iatic 
epidermal keratin ocytes (Lyons- Gio rdano cl ai, 1994) m ay be 
related to the demonstration of PAI-2 as a substrate for the 
tissu e- type transg lutamin ase in trophobl asts Oensen Cl ai, 1993) and 
to a n increased ke ratinocyte-specific transgllltaminase activi ty in 
PMA- treated m o use skin (G up ta cl ai, 1989; Fuchs, 1990). T his 
makes it tempting to specul ate that PA 1-2 might be a substrate for 
the ke rarinocyte-specific transglutam in ase and , as such , m ay playa 
role in the fo rmation of the insoluble cross-linked m e mbrane 
envelope (Thacher and R.ice, 1985) fou nd in th e cornified cells. 
T he rapid induction of both uPA and PAT-l mRNA in th e dermis 
and ofPA I-2 mR.NA in the suprabasa l ke ratinocytes suggests tha t it 
is a primary e ffect of PMA o n transcriptio n of the respective genes. 
All three genes have bee n shown to respond rapidl y to PMA 
trea tment ;11 ,,;11'0 (Stoppelli el ai, 1986; Sc hle llnin g et ai, 1987; 
Mayer el ai, 1988). T he slower induction of uP A, lIPAR, and PAl-l 
rnl~A in the epidermis might sugges t that this expressio n is due to 
a secondary efFect ofPM A. It has been shown by othe rs that a single 
application of tumor-promotin g phorbol esters to m o use skin 
indu ces the expression of several ea rly and secondary response 
genes and genes fo r growth f.,cto rs and cytokines in the epidermis 
(Holl aday el ai , 1992). T ransformin g growth factor-J31 h as been 
shown to regu late uPA, uPAR, aJld PAI-l mRNA synthes is ;11 ,,;11'0 
[Keski-Oja el al (1988), Lund cl al (1987, 1991 a); for reviews see 
Andreasen el al (1990) and Laiho and Kcski-Oja (1 989)] . It is an 
attrac tive hypothes is that the indu ction of the uPA system is ca used 
by o n e o r m ore of the cyto kincs synthes ized in thc m o usc skin. 
Applicatio n of nc utrali zing antibodies to se lected cytokine s could 
provide direct evidence of whe the r such mo lecular m ech anism s 
playa fun cti o nal rol e in the pl e iotropic responses of PM A-trea ted 
skin . 
We are .Rra ,~rll/,o Dr. D. Bd;II fi)/'llt e .~iJt oI, It" '""".'<' IIPA nt,d PA I-2 cDNAs, 
alld /cJ Dr. pfI'IIt/e,gas, jill' ,lte IIIOllse PA I-J eDNA. Tlte excc/lellt lec/Illical 
ass;s /(lIlcr ,if Dorte H olm , Kits /f ll LIIlld J akoiJsell , 1",C!rid FossaI' Larsc" , fwd Jette 
MaII de/ballll ' is .~m l'!litll )' ackll ", ,,lt((~ed. l.fIe Iltall/.: Mal}' McKell ",,), jill' edilillg lit e 
malluscript. This ,,,ork was slIJ'J.mrted by thc Dall;sl, Biotecllllolo,'!)' Pro,f:rnlllJ the 
Cell lerIor Mc(tical Bio(erilllolog)" 01111 lite D,,"isl, C Olleer Socicl)'. 
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